# Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

> **NCT02826798** · PHASE1 · COMPLETED · sponsor: **VBI Vaccines Inc.** · enrollment: 128 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** VBI-1501A 0.5 μg
- **DRUG:** VBI-1501A 1.0 μg
- **DRUG:** VBI-1501A 2.0 μg
- **DRUG:** VBI-1501 1.0 μg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02826798
- **Lead sponsor:** VBI Vaccines Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-23
- **Primary completion:** 2016-09-15
- **Final completion:** 2017-08-24
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2020-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826798, "Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02826798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*